Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug

Core Insights - Bioxytran, Inc. has successfully completed its second randomized double-blind, placebo-controlled clinical trial for its antiviral drug candidate, ProLectin-M, which is expected to inform the design of a phase 3 trial and will be submitted to the FDA [1][2] Group 1: Clinical Trial Results - The second randomized controlled trial aimed to confirm the results from an earlier Phase 2 study, which showed that ProLectin-M achieved undetectable levels of PCR and infection in less than one week for treated participants [2] - The successful execution of this trial strengthens the evidence for ProLectin-M as a rapid-acting oral therapeutic for various viral infections [2][4] Group 2: Future Plans and Publications - Comprehensive data from the third clinical trial, including safety and efficacy endpoints, is expected to be compiled for publication in a peer-reviewed medical journal in the coming weeks [3] - The company anticipates that the full results will be submitted for publication soon [3] Group 3: Company Vision and Impact - The CEO of Bioxytran, Dr. David Platt, stated that the completion of the trial represents a significant achievement and a potential paradigm shift in antiviral therapy, highlighting the rapid targeting of undetectable viral presence across multiple trials [4] - ProLectin-M is positioned as the first oral antiviral drug based on sugar chemistry, which could fundamentally change the management of viral outbreaks [4][6]